Sugi Predict
/ Targets
/ MAP3K8
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MAP3K8 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
PHASE4 | UNKNOWN |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| Clinical Evaluation of the Effect of Metformin in Sepsis |
PHASE3 | UNKNOWN |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer |
PHASE3 | RECRUITING |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
PHASE2 | COMPLETED |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations |
PHASE2 | RECRUITING |
| SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS |
PHASE2 | COMPLETED |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
PHASE2 | UNKNOWN |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer |
PHASE2 | UNKNOWN |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations |
PHASE2 | COMPLETED |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
PHASE2 | COMPLETED |
| Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma |
PHASE2 | UNKNOWN |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
PHASE1 | COMPLETED |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| Nilotinib in Huntington's Disease |
PHASE1 | UNKNOWN |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo |
nan | UNKNOWN |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| Molecular Analysis of Thoracic Malignancies |
nan | ENROLLING_BY_INVITATION |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| Biomarker Analysis of Gastrointestinal Cancer |
nan | UNKNOWN |
| Histiocytic Disorder Follow-up Study |
nan | RECRUITING |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients |
nan | COMPLETED |
| Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MAP3K8 binder may also engage these)